{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:36:00Z","timestamp":1777372560766,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11102-025-01512-5","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T18:27:45Z","timestamp":1741631265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Good response rates and predictors during the first year of cabergoline treatment in large invasive prolactinomas"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4957-9856","authenticated-orcid":false,"given":"Hayri","family":"Bostan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bekir","family":"Ucan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Duger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"Hepsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Kayihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Dilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilknur","family":"Ozturk Unsal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erman","family":"Cakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Kizilgul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"1512_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Endocrine society. Diagnosis and treatment of hyperprolactinemia: an endocrine society.clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"1512_CR2","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","volume":"108","author":"RS Auriemma","year":"2023","unstructured":"Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R (2023) Approach to the patient with prolactinoma. J Clin Endocrinol Metab 108:2400\u20132423. https:\/\/doi.org\/10.1210\/clinem\/dgad174","journal-title":"J Clin Endocrinol Metab"},{"key":"1512_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/13543784.11.6.787","volume":"11","author":"A Colao","year":"2002","unstructured":"Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11:787\u2013800. https:\/\/doi.org\/10.1517\/13543784.11.6.787","journal-title":"Expert Opin Investig Drugs"},{"key":"1512_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0012","volume":"160","author":"E Delgrange","year":"2009","unstructured":"Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistance to the prolactin-lowering effects of Cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160:747\u2013752. https:\/\/doi.org\/10.1530\/EJE-09-0012","journal-title":"Eur J Endocrinol"},{"key":"1512_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1023\/a:1026225625897","volume":"6","author":"ME Molitch","year":"2003","unstructured":"Molitch ME (2003) Dopamine resistance of prolactinomas. Pituitary 6:19\u201327. https:\/\/doi.org\/10.1023\/a:1026225625897","journal-title":"Pituitary"},{"key":"1512_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109:42\u201350. https:\/\/doi.org\/10.1159\/000495775","journal-title":"Neuroendocrinology"},{"key":"1512_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19:722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"key":"1512_CR8","doi-asserted-by":"publisher","first-page":"791633","DOI":"10.3389\/fendo.2021.791633","volume":"12","author":"C Pivonello","year":"2022","unstructured":"Pivonello C, Patalano R, Negri M et al (2022) Resistance to dopamine agonists in pituitary tumors: molecular mechanisms. Front Endocrinol 12:791633. https:\/\/doi.org\/10.3389\/fendo.2021.791633","journal-title":"Front Endocrinol"},{"key":"1512_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11102-023-01337-0","volume":"26","author":"L Billion","year":"2023","unstructured":"Billion L, Verleye A, Block C, Heyning PV, Herdt C (2023) Giant prolactinomas, a detailed analysis of 196 adult cases. Pituitary 26:529\u2013537. https:\/\/doi.org\/10.1007\/s11102-023-01337-0","journal-title":"Pituitary"},{"key":"1512_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3803\/EnM.2014.29.3.280","volume":"29","author":"Y Lee","year":"2014","unstructured":"Lee Y, Ku CR, Kim EH, Hong JW, Lee EJ, Kim SH (2014) Early prediction of long-term response to Cabergoline in patients with macroprolactinomas. Endocrinol Metab 29:280\u2013292. https:\/\/doi.org\/10.3803\/EnM.2014.29.3.280","journal-title":"Endocrinol Metab"},{"key":"1512_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/EJE-21-0561","volume":"185","author":"B Biagetti","year":"2021","unstructured":"Biagetti B, Sarria-Estrada S, Ng-Wong YK et al (2021) Shrinkage by the third month predicts long-term response of macroprolactinoma after Cabergoline. Eur J Endocrinol 185:587\u2013595. https:\/\/doi.org\/10.1530\/EJE-21-0561","journal-title":"Eur J Endocrinol"},{"key":"1512_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1530\/EJE-19-0753","volume":"182","author":"D Kim","year":"2020","unstructured":"Kim D, Ku CR, Kim K, Jung H, Lee EJ (2020) Prolactin\u2009\u2264\u20091 Ng\/mL predicts macroprolactinoma reduction after Cabergoline therapy. Eur J Endocrinol 182:177\u2013183. https:\/\/doi.org\/10.1530\/EJE-19-0753","journal-title":"Eur J Endocrinol"},{"key":"1512_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s12020-018-1703-4","volume":"62","author":"C Ara\u00fajo","year":"2018","unstructured":"Ara\u00fajo C, Marques O, Almeida R, Santos MJ (2018) Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses. Endocrine 62:470\u2013476. https:\/\/doi.org\/10.1007\/s12020-018-1703-4","journal-title":"Endocrine"},{"key":"1512_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1227\/00006123-199310000-00008","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610\u2013617. https:\/\/doi.org\/10.1227\/00006123-199310000-00008","journal-title":"Neurosurgery"},{"key":"1512_CR15","doi-asserted-by":"publisher","first-page":"e1506","DOI":"10.1210\/clinem\/dgad393","volume":"108","author":"C Himonakos","year":"2023","unstructured":"Himonakos C, Burman P, Borg H et al (2023) Long-term follow-up of 84 patients with giant prolactinomas-A Swedish nationwide study. J Clin Endocrinol Metab 108:e1506\u2013e1514. https:\/\/doi.org\/10.1210\/clinem\/dgad393","journal-title":"J Clin Endocrinol Metab"},{"key":"1512_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/cen.14541","volume":"95","author":"Y Rudman","year":"2021","unstructured":"Rudman Y, Duskin-Bitan H, Manisterski Y et al (2021) Long-term response to Cabergoline and multi-modal treatment in men with macroprolactinoma: does size really matter? Clin. Endocrinol 95:606\u2013617. https:\/\/doi.org\/10.1111\/cen.14541","journal-title":"Endocrinol"},{"key":"1512_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12020-015-0791-7","volume":"52","author":"E Espinosa","year":"2016","unstructured":"Espinosa E, Sosa E, Mendoza V, Ram\u00edrez C, Melgar V, Mercado M (2016) Giant prolactinomas: are they really different from ordinary macroprolactinomas? Endocrine 52:652\u2013659. https:\/\/doi.org\/10.1007\/s12020-015-0791-7","journal-title":"Endocrine"},{"key":"1512_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11102-016-0723-4","volume":"19","author":"I Shimon","year":"2016","unstructured":"Shimon I, Sosa E, Mendoza V et al (2016) Giant prolactinomas larger than 60\u00a0mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary 19:429\u2013436. https:\/\/doi.org\/10.1007\/s11102-016-0723-4","journal-title":"Pituitary"},{"key":"1512_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1677\/erc.0.0090103","volume":"9","author":"ML Jaffrain-Rea","year":"2002","unstructured":"Jaffrain-Rea ML, Di Stefano D, Minniti G et al (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9:103\u2013113. https:\/\/doi.org\/10.1677\/erc.0.0090103","journal-title":"Endocr Relat Cancer"},{"key":"1512_CR20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1365-2265.2006.02493.x","volume":"64","author":"E Delgrange","year":"2006","unstructured":"Delgrange E, Duprez T, Maiter D (2006) Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol 64:456\u2013462. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02493.x","journal-title":"Clin Endocrinol"},{"key":"1512_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3109\/02688697.2012.714817","volume":"27","author":"FL Vale","year":"2013","unstructured":"Vale FL, Deukmedjian AR, Hann S, Shah V, Morrison AD (2013) Medically treated prolactin-secreting pituitary adenomas: when should we operate? Br J Neurosurg 27:56\u201362. https:\/\/doi.org\/10.3109\/02688697.2012.714817","journal-title":"Br J Neurosurg"},{"key":"1512_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12902-020-0543-4","volume":"20","author":"E Vermeulen","year":"2020","unstructured":"Vermeulen E, D\u2019Haens J, Stadnik T et al (2020) Predictors of dopamine agonist resistance in prolactinoma patients. BMC Endocr Disord 20:68 https:\/\/doi.org\/10.1186\/s12902-020-0543-4","journal-title":"BMC Endocr Disord"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01512-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:53:22Z","timestamp":1746521602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01512-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1512"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01512-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"24 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was conducted per the ethical principles of the World Medical Association Declaration of Helsinki. Ethical approval for the present study was obtained from the Local Ethics Committee of D\u0131\u015fkap\u0131 Y\u0131ld\u0131r\u0131m Beyaz\u0131t Training and Research Hospital (newly Ankara Etlik City Hospital) (approval date: 11.01.2021; number: 102\/02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the retrospective design of this study, informed consent was not obtained from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}